论文部分内容阅读
目的 探讨降钙素(CT)基因高度甲基化在恶性血液病中的临床意义。方法 用限制性内切酶(HPaⅡ)消化 DNA,应用多聚酶链反应(PCR)技术检测了73例恶性血液病和对照组6例正常人以及24例非恶性血液病的 CT 基因的甲基化程度。结果 85.7%(12/14)急性淋巴细胞白血病(ALL)、60%(9/15)急性非淋巴细胞白血痛(ANLL)、80%(8/10)慢性粒细胞白血病(CML)、33.3%(5/15)淋巴瘤、2例(2/5)骨髓增生异常综合征(MDS)、1例(1/2)恶性组织细胞病(MH)、1例(1/3)慢性淋巴细胞白血病(CLL)和1例(1/9)多发性骨髓瘤(MM)的病人出现 CT基因高度甲基化阳性。而对照组6例正常人和24例非恶性血液病无1例阳性。结论 CT 基因高度甲基化可作为恶性血液病恶性克隆增殖的分子基因标志,为恶性血液病的诊断、微小残留病的监测及预示疾病的发展开辟了一条新途径。
Objective To investigate the clinical significance of calcitonin (CT) gene hypermethylation in hematologic malignancies. Methods DNA was digested with restriction endonuclease (HPa Ⅱ) and the methylation level of CT genes in 73 cases of hematologic malignancies and 6 cases of normal controls and 24 cases of non-hematologic malignancies was detected by polymerase chain reaction (PCR) . Results 85.7% (12/14) of acute lymphoblastic leukemia (ALL), 60% (9/15) of acute non-lymphocytic leukemia (ANLL), 80% (8/10) of chronic myeloid leukemia (CML), 33.3% (5/15) lymphoma, 2 cases (2/5) myelodysplastic syndrome (MDS), 1 case (1/2) malignant histiocytosis (MH), 1 case (CLL) and 1 patient (1/9) multiple myeloma (MM) patients with CT gene highly methylated. In the control group, 6 cases of normal people and 24 cases of non-malignant hematological disease were positive in 1 case. Conclusion CT hypermethylation can be used as a molecular marker for the proliferation of malignant hematological malignant clones. It provides a new way for the diagnosis of hematologic malignancies, monitoring of minimal residual disease and predicting the development of the disease.